Your World of Legal Intelligence
 Canada | +1 (343) 700 0450

Bristol-Myers Squibb Canada Co. v. Apotex Inc., 2017 FCA 190

Judgment Cited authorities 7 Cited in 14 Precedent Map Related
Vincent
JurisdictionFederal Jurisdiction (Canada)
Subject MatterPATENTS OF INVENTION,FOOD AND DRUG CONTROL
Citation2017 FCA 190
CourtCourt of Appeal (Canada)
Date18 September 2017
    • This document is available in original version only for vLex customers

      View this document and try vLex for 7 days
    • TRY VLEX
14 practice notes
  • Aux Sable Liquid Products LP c. JL Energy Transportation Inc.,
    • Canada
    • Federal Court (Canada)
    • May 6, 2019
    ...Ltd., [2000] EWHC Patents 49 , [2001] F.S.R. 16 ; Apotex Inc. v. Shire LLC, 2018 FC 637; Bristol-Myers Squibb Canada Co. v. Apotex Inc., 2017 FCA 190, 152 C.P.R. (4th) 265; Calgon Carbon Corporation v. North Bay (City), 2006 FC 1373 , 56 C.P.R. (4th) 281; Eli Lilly Canada Inc. v. Novopha......
  • Post-AstraZeneca: Has The Promise Doctrine Vanished From Patent Litigation? Likely, Yes
    • Canada
    • Mondaq Canada
    • October 15, 2018
    ...Footnotes 1 AstraZeneca Canada Inc. v. Apotex Inc., [2017] 1 SCR 943, 2017 SCC 36 ("AstraZeneca"). 2 Bristol-Meyers Squibb v. Apotex, 2017 FCA 190; Pfizer Canada Inc v. Apotex Inc, 2017 FC 774; Pfizer Canada Inc v. Teva Canada Limited, 2017 FC 777; Regents of the University of California v.......
  • Bristol-Myers Squibb Canada Co. v. Pharmascience Inc., 2021 FC 1
    • Canada
    • Federal Court (Canada)
    • January 12, 2021
    ...to inhibit a target implicated in a disease is doubtlessly a useful discovery” citing Bristol-Myers Squibb Canada Co v Apotex Inc, 2017 FCA 190 at para 40.  I accept the evidence of Dr. Weitz and Dr. Pinto that the in vitro testing demonstrated that apixaban selectively and pote......
  • Canadian Patent Litigation: Five Things To Watch In 2018
    • Canada
    • Mondaq Canada
    • February 16, 2018
    ...Federal Court of Appeal applied the Supreme Court's new utility test for the first time in Bristol-Myers Squibb Canada Co. v. Apotex Inc., 2017 FCA 190. The Court ruled that BMS's discovery of a compound that inhibited a biological target implicated in various diseases was a useful discover......
    • Request a trial to view additional results
3 cases
  • Aux Sable Liquid Products LP c. JL Energy Transportation Inc.,
    • Canada
    • Federal Court (Canada)
    • May 6, 2019
    ...Ltd., [2000] EWHC Patents 49 , [2001] F.S.R. 16 ; Apotex Inc. v. Shire LLC, 2018 FC 637; Bristol-Myers Squibb Canada Co. v. Apotex Inc., 2017 FCA 190, 152 C.P.R. (4th) 265; Calgon Carbon Corporation v. North Bay (City), 2006 FC 1373 , 56 C.P.R. (4th) 281; Eli Lilly Canada Inc. v. Novopha......
  • Bristol-Myers Squibb Canada Co. v. Pharmascience Inc., 2021 FC 1
    • Canada
    • Federal Court (Canada)
    • January 12, 2021
    ...to inhibit a target implicated in a disease is doubtlessly a useful discovery” citing Bristol-Myers Squibb Canada Co v Apotex Inc, 2017 FCA 190 at para 40.  I accept the evidence of Dr. Weitz and Dr. Pinto that the in vitro testing demonstrated that apixaban selectively and pote......
  • Aux Sable Liquid Products LP v. JL Energy Transportation Inc., 2019 FC 581
    • Canada
    • Canada (Federal) Federal Court (Canada)
    • May 6, 2019
    ...utility is to be measured with respect to the subject matter of the invention (see also Bristol-Myers Squibb Canada Co. v Apotex Inc., 2017 FCA 190 at para 35). [78] As previously noted, Aux Sable’s inutility arguments bear similarities to its arguments surrounding overbreadth. The expert e......
11 firm's commentaries
  • Post-AstraZeneca: Has The Promise Doctrine Vanished From Patent Litigation? Likely, Yes
    • Canada
    • Mondaq Canada
    • October 15, 2018
    ...Footnotes 1 AstraZeneca Canada Inc. v. Apotex Inc., [2017] 1 SCR 943, 2017 SCC 36 ("AstraZeneca"). 2 Bristol-Meyers Squibb v. Apotex, 2017 FCA 190; Pfizer Canada Inc v. Apotex Inc, 2017 FC 774; Pfizer Canada Inc v. Teva Canada Limited, 2017 FC 777; Regents of the University of California v.......
  • Canadian Patent Litigation: Five Things To Watch In 2018
    • Canada
    • Mondaq Canada
    • February 16, 2018
    ...Federal Court of Appeal applied the Supreme Court's new utility test for the first time in Bristol-Myers Squibb Canada Co. v. Apotex Inc., 2017 FCA 190. The Court ruled that BMS's discovery of a compound that inhibited a biological target implicated in various diseases was a useful discover......
  • Federal Court of Appeal Applies Supreme Court’s Utility Test to SPRYCEL Patent
    • Canada
    • JD Supra Canada
    • October 2, 2017
    ...guidance for the requirement of a scintilla of utility: Bristol-Myers Squibb v Apotex, 2017 FCA 190. Applications Judge – inutility due to failure to meet The compound dasatinib is sold by Bristol-Myers Squibb (BMS) as SPRYCEL, a drug used in the treatment of chronic myelogenous leukemia (C......
  • Promise Me No Promises? The Five-year Anniversary Of The Supreme Court's AstraZeneca Decision
    • Canada
    • Mondaq Canada
    • June 15, 2022
    ...of omeprazole". See AstraZeneca at para 61. 15. AstraZeneca at paras 59-63. 16. AstraZeneca at para 51. 17. Bristol-Myers Squibb v Apotex, 2017 FCA 190 [BMS 18. Bristol-Myers Squibb v Apotex, 2017 FC 296. 19. BMS Dasatinib at para 40. 20. Pfizer v Apotex, 2017 FC 774 [Pfizer ODV]. 21. Pfize......
    • Request a trial to view additional results

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT